Press Releases

UBX1325 Phase 2 study in DME currently enrolling, with additional Phase 2 study in AMD planned for 1H22 UNITY to present at invitation-only Eyecelerator innovation conference at AAO SOUTH SAN FRANCISCO, Calif. , Nov. 10, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc.

Patients with diabetic macular edema in higher dose cohorts showed a mean BCVA gain of approximately 10 ETDRS letters sustained through 24 weeks after a single intravitreal injection Patients with wet age-related macular degeneration showed improvement in visual acuity through 12 weeks supporting

SOUTH SAN FRANCISCO, Calif. , Nov. 03, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that from October 19, 2021 , through November 2, 2021 , the Compensation

SOUTH SAN FRANCISCO, Calif. , Oct. 06, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that from September 21, 2021 , through October 5, 2021 , the Compensation

Evidence of improvement in vision and retinal structure in patients with DME and AMD sustained through 12 weeks Sustained responses following single treatment with UBX1325 support durability of senolytic therapeutic approach; data builds on previously reported results at 8 weeks Study remains on

16 th Annual Citi BioPharma Conference on September 8-10, 2021 Morgan Stanley 19 th Annual Global Healthcare Conference on September 9-15, 2021 23 rd   H.C. Wainwright Global Investment Conference on September 13-15, 2021 Cantor Virtual Global Healthcare Conference on September 27-30, 2021 SOUTH

SOUTH SAN FRANCISCO, Calif. , Aug. 18, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that from August 3, 2021 , through August 17, 2021 , the Compensation

SOUTH SAN FRANCISCO, Calif. , Aug. 16, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that members of its senior management team will present at the upcoming H.C.

UBX1325 demonstrates favorable tolerability in Phase 1 safety study and improvement in visual acuity and central subfield thickness in majority of patients with diabetic macular edema (DME) and wet age-related macular degeneration (AMD) Results from Phase 1 study of UBX1325 in additional patients

SOUTH SAN FRANCISCO, Calif. , July 28, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that from July 13, 2021 , through July 27, 2021 , the Compensation